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Abstract 
We have proposed recently that the DO3A-N--(amino)propionate chelator and its amide conjugates 
are leads to targeted, high relaxivity, safe Contrast Agents for Magnetic Resonance Imaging. In this 
work we illustrate further the expeditious nature and robustness of the synthetic methodologies 
developed by preparing the DO3A-N-(-pyrenebutanamido)propionate chelator. Its Gd3+ chelate 
retains the optimized water exchange, high stability and inertness of the parent complex. The pyrene 
moiety imparts concentration-dependent self-assembly properties and aggregation-sensitive 
fluorescence emission to the Gd3+ complex. The Gd3+ complex displays pyrene-centred fluorescence 
whilst the Yb3+ and Nd3+ complexes exhibit sensitized lanthanide-centred near-infrared luminescence. 
The aggregated form of the complex displays high relaxivity (32 mM-1s-1, 20 MHz, 25 ºC) thanks to 
simultaneous optimization of the rotational correlation time and of the water exchange rate. The 
relaxivity is however still limited by chelate flexibility. This report demonstrates that the DO3A-N-(-
amino)propionate chelator is a valuable platform for constructing high relaxivity CA using simple 
design principles and robust chemistries accessible to most chemistry labs.  
  
Introduction 
Positron Emission Tomography (PET), Single Photon Emission Correlated Tomography (SPECT), 
Magnetic Resonance Imaging (MRI), Ultra Sound (US), and X-ray Computerized Axial Tomography 
(CAT), are imaging modalities used nowadays regularly in hospitals for diagnostic and prognostic 
purposes.1 MRI has become in recent years the most useful imaging modality in the clinical setup. This 
results from its superb spatial resolution, use of non-ionizing radiation (radiofrequencies and magnetic 
fields), depth independent imaging and the possibility of repeated imaging to offset the low detection 
sensitivity of MRI which is intrinsic to the Nuclear Magnetic Resonance phenomenon. Signal intensity 
differences in MRI (contrast) arise mainly from intrinsic differences of the relaxation times (T1,2) of 
the water protons of tissues. The contrast between normal and diseased tissues can be dramatically 
improved by paramagnetic Contrast Agents (CA) (Gd3+, Mn2+, stable nitroxide radicals, iron oxide 
nanoparticles, etc.), which shorten the relaxation times of the water protons.2 Relaxivity (r1,2), which is 
the paramagnetic enhancement of water proton relaxation rates R1,2 (R1,2 = 1/T1,2) normalized to 1 mM 
concentration, measures CA efficacy.2,3 The currently used CAs for T1-weighted MRI imaging are 
Gd3+ chelates of linear (DTPA-type) or macrocyclic (DOTA-type) poly(aminocarboxylate) chelators. 
Due to its long electronic relaxation times and high paramagnetism, Gd3+ efficiently enhances T1 
relaxation, resulting in signal intensity enhancement and bright images- positive contrast.4 High 
relaxivity CA can lead to T1 reductions sufficient to generate effective contrast at low doses. 
Moreover, delivering CA to diseased areas can allow further dose reduction. Effective contrast at low 
CA doses (CA in clinical use are normally used at a dose of 0.1 mmol/Kg) became more important 
recently with the identification of the Nephrogenic Systemic Fibrosys (NSF) which is a debilitating 
and even deadly condition, associated to in vivo Gd3+ release from Gd-based CA.5 In fact, free (non-
complexed) Gd3+ (and all other Ln3+ ions) are acutely toxic. Most NSF cases have been associated with 
the use of Gd3+ DTPA-type complexes, particularly Gd(DTPA-bis-amide) CA.6 Low thermodynamic 
stability and kinetic lability, coupled to slow kidney clearance, results in extensive complex 
demetallation in vivo.7 Macrocyclic, DOTA-type Gd3+ complexes are generally considered safe given 
their higher thermodynamic stability and kinetic inertness.8 Chelates displaying simultaneous 
optimization of the molecular parameters that govern relaxivity, namely the rotational correlation time 
(R), the water exchange rate (kex=1/M) and the electronic relaxation parameters, are expected to 
display very high relaxivities.9 There are well established strategies for tuning R and kex into the 
optimal range to attain high relaxivities at intermediate fields relevant for clinical MRI. Tuning the 
Gd3+ ion electronic relaxation parameters turns out to be more challenging.10 Increasing the molecular 
weight of chelates leads to longer rotational correlation times (R) (slower tumbling rates) enhancing 
CA relaxivity at intermediate fields. Self-assembly of amphiphilic chelates into micelle-type 
supramolecular structures,11 non-covalent association with Serum Albumin12 and covalent attachment 
of chelates to macromolecular and nanoobjects (proteins,13 dendrimers,14 nanoparticles,15 viral 
capsules,16 quantum dots,17 etc.) are well established strategies to tune R. Replacement of an 
ethylenediamine by a propylenediamine bridge or a pendant acetate by a propionate group on the 
DOTA and DTPA scaffolds enforces steric compression around the water binding site on Gd3+ 
complexes, leading to accelerated water exchange.11,18,19 A pendant propionate group leads to water 
exchange rate enhancements suitable for attaining high relaxivities at intermediate fields, without 
compromising the thermodynamic and kinetic stability of the chelates.18,20,21 Still, connecting 
linkers/spacers permit fast local rotational motions of the immobilized chelates superimposed to global 
slow rotational motions of the (entire) macromolecular object, resulting in suboptimal effective 
rotational correlation times.11,15 
Endowing targeted high relaxivity Gd3+ chelates with fluorescence reporting capability results in 
bimodal MRI/fluorescence imaging agents. This approach has the potential to improve CA 
performance: the high detection sensitivity of fluorescence complements the low detection sensitivity 
of MRI, whilst the depth independent properties of MRI complement the limited light crossing into 
live tissues.22 Conjugates of metal chelate-fluorophores,23 quantum dots17,24, silica nanoparticles25,26 
and other nanomaterials functionalised with Gd3+ chelates have been described as bimodal 
MRI/fluorescence imaging agents. The aggregation sensitive fluorescence properties of the pyrene 
fluorophore27 make pyrene conjugates especially attractive as “responsive” probes for structural,28 
biochemical and cellular studies29 and as chemical sensors.30 Moreover, pyrene has been used as 
antenna for sensitizing near infrared (NIR) emitting Ln3+ ions (Yb3+, Nd3+ and Er3+) in DOTA and 
DTPA chelates.31,32 
We have recently described methodologies for the synthesis of the DO3A-N-(-amino)propionate 
chelator and for preparing its amide conjugates.18,21 Gd3+ complexes of those amide conjugates retain 
the optimal water exchange, high stability and kinetic inertness of the parent complex.18 In this work 
we describe the synthesis of the pyrenebutyric acid conjugate of the DO3A-N-(-amino)propionate 
chelator and its Ln3+ complexes. The effect of self-assembly on the relaxivity and fluorescence 
properties of the Gd[DO3A-N-(-pyrenebutanamido)propionate]complex was studied by relaxometry 
and steady state fluorescence. The potential of the pyrene moiety to sensitize NIR emitting Ln3+ ions 
has been also addressed. 
Results and Discussion 
 
Synthesis  
 
The DO3A-N-(-pyrenebutanamido)propionate chelator (L) was synthesised following the (indirect) 
methodology proposed before for amide conjugates of the DO3A-N-(-amino)propionate chelator 
(Scheme 1).21 
 
 
Scheme 1. Synthetic pathway for the metal chelator DO3A-N-(α-pyrenebutanamido)propionate (L) and its Ln3+ 
complexes LnL: a) K2CO3/MeCN; b) i. TFA/DCM, ii. Ethyl bromoacetate, K2CO3/MeCN; c) i. Dowex1X2-OH-
, ii. Elution with hydrochloric acid 0.1 M; d) LnCl3. xH2O. 
 
 
 
 
 
 
 
 
 
The N-(-pyrenebutanamido)propionate  pendant group was introduced, early on the synthesis, into 
the cyclen scaffold via Michael addition of the dehydroalanine (Pyrene, Boc)--AlaOMe reactive 
block (4). Synthetic block (4) was prepared in 2 steps in 70% overall yield following the procedure 
developed by Ferreira and co-workers (Scheme 2).33 
 
 
 
Scheme 2. Synthesis of the dehydroalanine (Pyrene, Boc)--AlaOMe reactive block (4): a) i. TEA 2 molar 
equivalents/MeCN, ii. DCC/HOBt; b) Boc2O, DMAP, dry MeCN.  
 
After removing the tert-butyloxycarbonyl protecting group from the monoalkylated intermediate (6) 
with TFA, one pot N-alkylation of the cyclen scaffold with ethyl bromoacetate afforded prochelator 7. 
Alkaline deprotection of 7 with Dowex1X2-OH- resin, followed by resin elution with diluted 
hydrochloric acid afforded the DO3A-N-(α-pyrenebutanamido)propionate chelator (L) as 
hydrochloride in 30% overall yield over 3 steps. Recently, Caravan and co-workers have reported a 
similar pathway for the synthesis of conjugates of the DO3A-N-(-amino)propionate chelator.34 The 
synthesis of the DO3A-N-(-pyrenebutanamido)propionate chelator further supports the use of the 
indirect pathway for amide conjugates of the DO3A-N-(-amino)propionate chelator.  
 
 
 
 
 
 
Relaxometric studies of the GdL complex 
The concentration dependence of the paramagnetic water proton relaxation rate (R1p) was evaluated for 
GdL (20 MHz, 25 ºC, pH 7.0) in the concentration range 0.05-5.0 mM (Figure 1). 
 
Figure 1. Concentration dependence of the paramagnetic water proton longitudinal relaxation rate R1p = (R1obs-
R1d) for GdL (20 MHz, 25 ºC, pH 7.0). 
 
The paramagnetic longitudinal relaxation rate data vs [GdL] define two straight lines with different 
slopes. This behaviour is characteristic of chelate self-assembly in aqueous solution, presumably into 
micelle-type structures, driven by the hydrophobic effect.11 The break point gives an estimation of the 
critical micelle concentration, cmc (0.60±0.02  mM), for GdL. Below the cmc, the complex is in a 
monomeric, non-aggregated, form in solution (Equation 1). Above the cmc, it is present in the form of 
aggregates as well as monomers whose concentration corresponds to the cmc (Equation 2).  
 
R1p = R1
obs – R1d = r1n.a  CGd     (1) 
R1p = R1
obs – R1d = (r1n.a – r1a)cmc + r1a CGd  (2) 
 
R1
d is the diamagnetic contribution to the longitudinal relaxation rate (the relaxation rate of pure water), r1n.a 
(6.86±0.03 mM-1s-1) represents the relaxivity of the free, non-aggregated Gd3+ chelate, r1a (33.11±0.04 mM-1s-1), 
is the relaxivity of the micellar (aggregated) form and CGd is the analytical Gd3+ concentration. 
 
The micellar nature of GdL above the cmc (5.0 mM, pH 7.0) was confirmed by Dynamic Light 
Scattering (DLS) analysis (Figure S1). A bimodal intensity distribution, with the main population of 
particles displaying an average radius of 1.7 nm and a minor population exhibiting an average radius 
of 73 nm, was obtained by DLS, resulting in a population weighted mean hydrodynamic radius, 
expressed by the z-average parameter, of 49 nm.  The temperature (Figure S2) and the pH dependence 
(Figure S3) of the paramagnetic water proton relaxation rate was studied at 20 MHz.  
Transmetallation studies against Zn2+ ions were also performed to evaluate the kinetic inertness of the 
complex (Figure S4). The temperature dependence study strongly suggests that below 50 °C, the 
relaxivity is not limited by slow water exchange. The pH-dependence and the transmetallation studies 
indicate that the GdL complex, like its non-associating Gd[DO3A-N-(-benzoylamido)propionate] 
analogue, is stable towards protonation-assisted demetallation and inert towards transmetallation with 
Zn2+.21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17O NMR and 1H NMRD studies 
The magnetic field dependence of the longitudinal water proton relaxivities (1H NMRD profiles) of 
GdL was recorded at 25 °C and 37 °C in the frequency range 0.01 to 80 MHz and at concentrations 
below (Figure 3) and above (Figures 2c) the cmc.  
 
 
Figure 2. Temperature dependence of (a) reduced longitudinal, T1r () and transverse, T2r () relaxation times 
and (b) chemical shifts (r) of a micellar aqueous solution of GdL at 11.7 T (5.0 mM, pH 7.0); (c) NMRD 
profiles of the aggregated micellar state (2.5 mM, pH 7.0)  at 25 °C  (■) and  37 °C (▲)  after subtraction of the 
relaxation contribution of the monomer form. The curves represent results from the simultaneous fittings as 
described in the text. 
 
 
 
 
 
 
 
 Figure 3. 1H nuclear magnetic relaxation dispersion (NMRD) profiles of GdL in the monomer state at 0.3 mM 
at 25 ºC (▲) and 37 ºC (■). The curves represent results from the fittings as described in the text. 
 
The NMRD curves are influenced by many parameters, the most important being the hydration 
number (q), the water exchange rate (kex), the electron relaxation parameters (v and 2) and the 
rotational correlation time (R).The NMRD measurements have been completed with 17O NMR data 
(Figure 2a,b). Indeed, from variable temperature 17O T2 measurements, one can accurately determine 
the water exchange rate. The rotational correlation time can be assessed by variable temperature 17O T1 
measurements. On the other hand, variable temperature measurements of the chemical shift difference 
between bulk and bound water (Δωr), give an indication of the q value. 
The proton relaxation rates measured above the cmc represent the sum of the relaxivity contribution of 
the monomer complex, present at a concentration equal to the cmc, and the relaxivity contribution of 
the aggregated state. In order to calculate the relaxivity of the aggregated form, the relaxivity 
contribution of the monomer has been subtracted from the relaxation rates measured above the cmc. 
These profiles present the characteristic high field peak typical of slowly tumbling Gd3+ complexes. 
The 17O NMR measurements have been performed at 5.0 mM concentration, largely above the cmc 
(0.6 mM). Under these conditions, one can consider that the rotational dynamics, as assessed by 17O T1 
data, corresponds to the micellar state. Therefore, the 17O NMR data have been fitted together with the 
NMRD curves of the micellar state to the Solomon-Bloembergen-Morgan theory by including the 
Lipari-Szabo treatment for the description of the rotational motion (Table 1).35  
 
 
 
 
 
Table 1. Best fit parameters obtained for the aggregated form of GdL from the simultaneous analysis of the 17O 
NMR and 1H NMRD data and for the monomer from NMRD data 
 
Parameter Aggregated form Monomer 
H¹ [kJmol-1] 21.5 ± 1.5 21.5 
kex298 [107 s-1] 6.2 ± 0.5 6.2 
g298 [ps] 3780 ± 100 116 ± 5 
lO298 [ps] 930 ± 50 ------- 
S2 0.24±0.02 ------- 
lH298/lO298 0.80±0.05 ------- 
Eg[kJmol-1] 25.4 ± 0.7 ------- 
El[kJmol-1] 12± 1 24.3 ± 0.2 
2 [1020 s-1] 0.033 ± 0.004 0.38 ± 0.04 
v298 [ps] 53 ± 5 6.3 ± 0.5 
A/ћ [106 rads-1] -3. 2 ± 0.4 ------- 
Parameters underlined have been fixed;  
RO298 values from 17O T1 data. 
 
In this approach, two kinds of motion are assumed to modulate the interaction causing the relaxation, 
namely a rapid, local motion which lies in the extreme narrowing limit and a slower, global motion.  
We calculate therefore g, the correlation time for the global motion (common to the whole micelle), 
and l, the correlation time for the fast local motion, which is specific for the individual relaxation axis, 
and thus related to the motion of the individual Gd3+ chelate units. The generalized order parameter, S, 
is a model-independent measure of the degree of spatial restriction of the local motion, with S = 0 if 
the internal motion is isotropic and S = 1 if the motion is completely restricted. 
It was assumed that the GdL complex has one inner sphere water molecule (q = 1) like the low 
molecular weight amide analogue Gd[DO3A-N-(α-benzoylamido)propionate]21 and the parent amine 
Gd[DO3A-N-(α-amino)propionate].18 This assumption was confirmed by the value obtained for the 
scalar coupling parameter (A/ћ = -3.2106 rad s-1).36 
The NMRD curves of the monomer sample (0.3 mM) have been analyzed by fixing the water 
exchange parameters (kex
298, H‡) to those obtained from the 17O NMR data. In the fits, we have fixed 
the rGdH distance to 3.10 Å and the distance of closest approach of the bulk water protons to the Gd
3+, 
aGdH, to 3.65 Å. The diffusion constant has been fixed to 2310-10 m2/s and its activation energy to 20 
kJ/mol. 
The NMRD profile for the monomeric form is characteristic of low molecular weight complexes 
(Figure 3). The relaxivity at intermediate field (5.9 mM-1 s-1; 25 ºC, 20 MHz) is dominated by fast 
rotation in solution as indicated by the short R value obtained (116 ps). In contrast, above the cmc the 
NMRD profile of GdL displays a hump at intermediate field, typical of slow tumbling species (Figure 
2c).11,15,35 
The relaxivity decreases with increasing temperature, indicating that it is not limited by slow water 
exchange. The same behaviour was previously observed for gold nanoparticles functionalised with the 
analogous cysteine conjugate Gd[DO3A-N-(α-cystamido)propionate].15 The water exchange rate on 
GdL is similar to that reported for the low molecular weight amide analogue Gd[DO3A-N-(α-
benzoylamido)propionate]21 and slightly higher than that reported for the parent Gd[DO3A-N-(α-
amino)propionate]18 complex (kex
298/107= 6.2, 5.7 and 4.0 s-1, respectively). This value is in the ideal 
range for attaining high relaxivities at intermediate magnetic fields relevant for clinical applications.19  
The Lipari-Szabo analysis of the longitudinal 1H and 17O relaxation rates allows separating fast local 
rotational motions of the chelate (Rl = 930 ps) from the global rotational correlation time (Rg = 3780 
ps) of the micellar aggregate.  
The value of the order parameter for GdL (S2 = 0.24) is similar to those calculated for amphiphilic 
DOTA-type complexes functionalised with hexadecyl alkyl chains: Gd(DOTASAC18)37 and 
Gd(DOTAMAP-En-C18)38 (S2 = 0.24 and 0.28, respectively) (Figure 4 and Table 2). 
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Figure 4. Structure of amphiphilic DOTA-type ligands compared in Table 2 and discussed in the text. 
 
 
 
Table 2. Molecular parameters for amphiphilic DOTA-type complexes 
Chelate MW 
(g/mol) 
cmc 
(mM) 
l298 
(ps) 
g298 
(ps) 
S2 kex298 
(/107s-1) 
r1m, f 
(mM-1s-1) 
GdL1a 881.2 0.06 330 2810 0.28 0.48 20.7 
GdL2b 881.2 - 271 2696 0.21 8.12 24.2 
GdL3c 1036 <0.1 820 4700 0.70 0.34 34.8 
GdL4d 1285 0.004 135 5206 0.78 0.30 35 
GdLe 857 0.6 930 3780 0.24 6.2 32.2 
aref 37; bref. 38; cref.40; dref.39;ethis work; f(20MHz, 25ºC) 
 
 
Complexes functionalised with two long alkyl chains, Gd[(C18)2DOTAda)]39 and 
Gd[(DOTA(GAC12)2)]40, are characterised by substantially higher order parameters (S2 = 0.78 and 
0.70, respectively). Tighter packing of the monomers and double anchoring through adjacent sites into 
the micelle structure restrict internal rotational movements of the chelates. 
Moreover, the complex Gd[(C18)2DOTAda)] functionalised with two alkyl chains displays a much 
lower cmc value than the complex Gd(DOTASAC18) functionalised with one alkyl chain. In this 
respect, the GdL complex displays a relatively high cmc value (0.6 vs 0.06 and 0.004 mM for 
Gd[(C18)2DOTAda)] and Gd(DOTASAC18), respectively) reflecting probably the aromatic nature of 
the pyrene lipophylic moiety and the deviation of the overall shape of the conjugate from the wedge-
like geometry which would be ideal for micelle formation. 
The relaxivity displayed by the micellar form of GdL (32 mM-1s-1, 20 MHz, 25 °C) is substantially 
higher than that shown by the Gd(DOTASAC18) and Gd(DOTAMAP-En-C18) complexes (24.2 and 
20.7 mM-1s-1, respectively) and it is similar to the relaxivity of the double chain chelates 
Gd[(C18)2DOTAda)] and Gd[(DOTA(GAC12)2)] (35 and 34.8 mM-1s-1, respectively). The high 
relaxivity of the double chain chelates has been ascribed to restricted local motions of the complex (S2 
= 0.78) and to the slow global rotational motion (g). Importantly, GdL displays a relaxivity similar to 
that of the double chain chelates, despite a lower global rotational correlation time (g= 3780 vs 5206 
and 4700 ps for Gd[(C18)2DOTAda)] and Gd[(DOTA(GAC12)2)], respectively) and a substantially 
lower degree of coupling of global and local rotational motions (higher flexibility) (S2 = 0.24 vs 0.78 
and 0.70 for Gd[(C18)2DOTAda)] and Gd[(DOTA(GAC12)2)], respectively). Importantly, the 
relaxivity of the double chain chelates is limited by slow water exchange (kex
298/107= 6.2 vs 0.30 and 
0.34 s-1 for GdL and Gd[(C18)2DOTAda)] and Gd[(DOTA(GAC12)2)], respectively). 
 
 
 
The high relaxivity attained by GdL can be thus ascribed to simultaneous optimization of R and kex. 
The optimization of the rotational dynamics of complexes has been firmly established for relaxivity 
enhancement at intermediate fields. The simultaneous optimization of R and kex is far more demanding 
and often achieved at the expense of complex stability compromising potential biological applications. 
This study highlights the importance of simultaneous optimization of all molecular parameters in order 
to attain high relaxivities and provides further support for our claim that amide conjugates of the 
DO3A-N--aminopropionate chelator are valuable synthons for constructing high relaxivity safe CA 
for MRI.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Luminescence studies 
The Gd[(DO3A-N-(α-pyrenebutanamido)propionate)] complex was designed as a bimodal 
MRI/fluorescence probe. The pyrene fluorophore was selected to impart self-assembly properties and 
concentration-dependent fluorescence reporting capability to the paramagnetic complex.27 
The absorption (Figure S6) and the fluorescence emission properties (Figure S7) of the free ligand L 
and the GdL complex were studied in non-deoxygenated water (pH 7.0) at concentrations well below 
the cmc by UV-Vis and steady-state fluorescence spectroscopy (Table 3). 
 
At concentrations below the cmc (cmc = 2.7 mM for L, see below, and 0.6 mM for GdL), L and GdL 
display similar absorption spectra in the region characteristic of pyrene (300-350 nm) assigned to 
intraligand * transitions.32 Selective irradiation of the pyrene chromophore on L and GdL at 345 
nm yields fluorescence spectra displaying vibronically structured features, assigned to intraligand 
1* transitions, characteristic of pyrene monomer emission (Figure S5).32,41At the concentration 
studied (well below the cmc) no excimer emission (broad featureless band with an emission with an 
apparent maximum located at 490-500 nm) was observed for both the free ligand and the Gd3+ 
complex. The fluorescence quantum yields for L and for the pyrene-centred emission in GdL are of 
the same order of magnitude as those reported for other pyrene conjugates.  
Complex formation with paramagnetic Gd3+ seems to have only a minor effect on the fluorescence 
quantum yield of L.41 
 
 
Table 3 - Maximum absorption (abs) and emission wavelengths (em), molar extinction coefficients () 
and fluorescence quantum yields (F) for ligand L and GdL complex (ex 345 nm) in non-deoxygenated 
water at concentrations below the cmc. 
abs(nm) 
(/104 M-1cm-1)b 
em(nm) Fa,c 
L GdL L GdL L GdL 
344 (3.26) 
328 (2.35) 
314 (1.00) 
277 (3.60) 
266 (2.05) 
243 (5.62) 
344 (4.43) 
328 (3.20) 
314 (1.59) 
277 (5.59) 
266 (3.78) 
243 (9.19) 
377 
397 
417 
377 
398 
418 
0.22 0.17 
aRelative to anthracene in ethanol ( = 0.27) 
bLigand and complex at 1x10-5 M concentration 
cLigand and complex at 1x10-6 M concentration, non-deoxygenated solutions 
We envisaged that it could be possible to monitor the self-assembly process of L and GdL by taking 
advantage of the aggregation-sensitive fluorescence properties of the pyrenyl moiety.27 With this aim, 
we studied by steady-state fluorescence the effect of the concentration on the fluorescence properties 
of L (Figure S7) and GdL (Figure 5). 
 
Figure 5. Normalized fluorescence spectra for GdL in non-deoxygenated water over the concentration range 
1x10-7 - 5x10-3 M (exc= 345 nm). Inset- changes in the emission properties of GdL as ratio of the fluorescence 
emission intensity for the excimer (IE, 490 nm) and for the monomer (IM, 377 nm) (IE/IM) as a function of GdL 
concentration. 
 
For low micromolar concentrations of L and GdL, the fluorescence spectra display the characteristic 
vibronically structured pyrene monomer emission band. For higher (low milimolar) concentrations, the 
intensity of the monomer emission band is reduced and a new broad, red-shifted, featureless band, 
assigned to excimer formation, appears. The concentration dependence of the ratio of fluorescence 
emission intensity for the excimer (490 nm) and for the monomer (377 nm) (IE/IM) was used to 
determine independently the cmc for L (Figure S7) and GdL (Figure 5) by fitting the experimental 
data points to a sigmoidal curve model (Table S1).42,43 A cmc value of approximately 0.64 mM, in 
excellent agreement with the value determined by relaxometry (0.60 mM), was derived for GdL from 
the fluorescence study (Figure 5). A much higher cmc value (2.7 mM) was determined for the free 
ligand (Figure S7), reflecting the ionization state (multi-charged) of the free metal chelator. Below the 
cmc, the ligand and complex are molecularly dissolved and the fluorescence arises from the decay of 
excited monomers. Above the cmc, fluorescence emission arises predominantly from the decay of 
excited dimers- excimers. Higher concentrations of GdL increase the number of micelles and enhance 
excimer formation and the corresponding fluorescence emission intensity. Two different mechanisms 
have been established for excimer emission: diffusive encounter of an excited monomer with a ground 
state molecule and the direct excitation of (pre-associated) ground state dimers. The partitioning of the 
different modes of excimer formation depends on the fluidity of the micelle environment. Time-
resolved fluorescence experiments suggest that the diffusive mechanism is the main contributor to  
excimer formation in cationic gemini surfactants containing a pyrene moiety and a long alkyl chain.44 
The order parameter determined for the micellar form of GdL (S2 = 0.24) indicates that the micelles are 
fluid, suggesting that the diffusive mechanism might be responsible for excimer formation. 
Deciphering the mechanism of excimer formation in GdL micelles is outside the scope of the present 
study. The pyrene-centered fluorescence of GdL effectively provides this complex with 
MRI/fluorescence bimodal imaging agent activity. From the practical point of view, the pyrene centred 
fluorescence of GdL could be used for imaging studies in small animal models, for ex vivo 
characterization of tissue distribution, cell internalization and intracellular chelate localization and 
studies with cell lines.45 
Lanthanide centred fluorescence in the visible (Eu3+ and Tb3+) and in the NIR region (Nd3+, Yb3+) are 
well suited for biological imaging: enhanced light penetration into biological tissues (especially in the 
NIR region); elimination of interference from tissue auto-fluorescence using time-gating techniques; 
long wavelength excitation, far into the visible region. Very low molar absortivities (f-f transitions are 
forbidden by Laporte´s and parity rules) make the direct excitation of Ln3+ ions impracticable. The 
formation of emissive Ln3+ excited states requires sensitization by sensitizing groups that absorb 
excitation light and transfer the resulting energy to the Ln3+ excited states (antenna effect), usually 
through ligand-centred triplet excited states.46 In this study, we tested the possibility of using the 
pyrene chromophore to sensitize near infrared emitting Ln3+ ions in the corresponding LnL complexes 
(Ln= Nd and Yb) (Figure 6). 
 Figure 6. Absorbance (black), excitation (λem= 1064 nm, violet) and emission (λexc= 344 nm, red) spectra for the 
NdL complex (a), and YbL complex (b) in water. 
 
Emission spectra of the NdL and YbL complexes under ligand excitation exhibit metal-centred NIR 
emission bands at ca 1064 nm (4F3/2⟶4F13/2) for NdL and a band with an apparent maximum at ca 
1000 nm (2F 5/2⟶2F7/2) for YbL.31,32 The excitation spectra for both luminescent Nd3+ and Yb3+ 
complexes are similar with each other and match well the profile of the corresponding absorption 
spectra as an indication that the sensitization of the lanthanide luminescence is occurring through the 
same electronic levels centred on pyrene.   
Interaction of GdL with Human Serum Albumin (HSA) 
The self-assembly of chelates into supramolecular structures (as discussed in this work) and binding to 
Serum Albumin (HSA) are robust strategies to enhance chelate relaxivity via optimization of R. In 
addition to relaxivity enhancement, self-assembly and binding of chelates to HSA slow down CA 
leakage into the interstitial compartment, providing an extended time window for vasculature imaging 
(MRI angiography).47 The binding affinity of GdL to HSA was assessed by Proton Relaxation 
Enhancement (PRE) measurements. The PRE methods are tailored to determine the differences in the 
NMR water solvent relaxation rates between protein-bound (resulting in an increase of the relaxation 
rates) and free substrates. Experimentally, it consists of measuring the water proton relaxation rates 
R1obs in solution at increasing concentrations of the protein while keeping the concentration of the 
metal chelate constant (E-titration) or  vice-versa (M-titration). The data obtained for the E-titration 
using a GdL concentration below the cmc (0.1 mM) and increasing HSA concentrations (Figure 7) 
were fitted to a one site binding model (Equation S1).     
 
Figure 7. Proton Relaxation Enhancement data (20 MHz, pH 7.4) to assess HSA binding of GdL: E-titration at 
0.1 mM GdL concentration at 25°C and 37°C. 
The fitting affords an estimation of the relaxivity of the HSA-bound form, r1
c (53.1±6.7 and 47.0±5.6 
mM-1s-1 at 25 and 37 ºC, respectively) and an apparent HSA-GdL association constant, KA (KA= 1/Kd) 
((1.9± 0.1) 103 and (1.7± 0.1)103 M-1 at 25 and 37 ºC respectively). These values correspond to 
binding affinities similar to Gd(BOPTA)2- but weaker than for MS-325, two blood pool agents 
presenting strong HSA binding.48 In the limiting E-titration conditions ([GdL]= 0.1 mM and [HSA]= 
4%) the fraction of bound chelate can be estimated as higher than 90%. These values are in line with 
those reported recently by Caravan for similar amide conjugates.12 It is known that HSA has multiple 
binding sites. Among the many studies published on HSA binding of Gd3+ complexes, typically those 
involving ultrafiltration experiments have reported binding to more than one independent sites with 
different binding constants.49,50 Those stepwise binding constants show that one binding site is much 
stronger than the others, justifying the common use a 1:1 binding isotherm to interpret the relaxometric 
data for albumin binding of Gd3+ complexes.51 In fact, most often relaxometric data alone do not allow 
for distinguishing between different binding models. An independent evaluation of KA and n may be, in 
principle, pursued through the analysis of the data obtained from an M-titration, in which a fixed 
concentration of HSA is titrated with the Gd3+ complex. The titration of 4% HSA with GdL is 
restricted to the narrow range of concentrations bellow cmc precluding quantitative analysis of the 
data. The interaction of GdL with HSA is prone to modulate the biodistribution of GdL as recently 
reported for similar conjugates.12,52  
Biodistribution studies 
The biodistribution profile of GdL was obtained after 1 and 24 hours post-injection (pi) using the 
153Sm3+-labelled surrogate complex (Figure 8 and Table S2). 
 
Figure 8. Biodistribution, stated as percentage of injected dose per gram of organ (%ID/g), of 153SmL in Wistar 
rats 1 and 24 hours after i.v. injection. Results are the mean of 4 animals. 
 
A recent Patent claims that peptides derivatised with pyrene are able to cross the blood-brain barrier 
thanks to (presumably) a correct lipophylicity/hydrophylicity balance imparted by the pyrene moiety.53 
This intriguing possibility was considered during the biodistribution study. The 153SmL chelate 
displays biodistribution profiles at 1 and 24 hours pi similar to other micellar systems.54 After 1 hour pi 
there is substantial activity in the blood, liver, spleen and lungs. The high activity in the blood after 1 
hour pi reflects the micellar nature of the CA and its strong association with HSA, which slows down 
leakage of the complex into the interstitial compartment. The complex follows both hepatic and renal 
elimination. The hepatic and spleen uptake reflects the micellar nature of the CA and the role played 
by resident macrophages in the liver and spleen (Reticulo Endothelial System, RES) in clearing 
particulate material from the blood. The activity in the lungs might again reflect the retention of 
particulate material in narrow blood vessels and the extensive vascularisation of that organ and thus 
the high blood content of the lungs. The increase in activity in the spleen and liver after 24 hours pi 
correlates with the activity clearance from the blood and lungs, suggesting particle retention on those 
organs. Interestingly, after 1 hour pi, a low activity is measurable in the brain/cerebellum, suggesting 
that the complex might cross the blood-brain barrier. This possibility deserves further investigation. 
 
Conclusions 
The pyrenebutyric acid conjugate of the DO3A-N-(-amino)propionate chelator was synthesised 
following synthetic methodologies reported previously by us. The lipophilic pyrene moiety imparts 
concentration-dependent self-assembly ability (presumably into micelles) to the Gd[DO3A-N-(α-
pyrenebutanamido)propionate] chelate. The aggregated form of the Gd3+ chelate displays high 
relaxivity thanks to simultaneous optimization of the rotational correlation time and of the water 
exchange rate. Nonetheless, the relaxivity is still limited by internal flexibility. The Gd3+ complex 
displays pyrene-centred fluorescence properties sensitive to its aggregation state. The Nd3+ and Yb3+ 
complexes exhibit lanthanide-centred sensitized NIR emission. The surrogate 153Sm3+ complex 
displays a biodistribution profile similar to other micellar systems. Interesting applications of this 
probe can be based on the recent report that carbon-based nanomaterials (graphene, graphene oxide, 
carbon nanotubes) functionalized non-covalently with pyrene conjugates are promising for the 
development of exquisite probes for biological processes.55 In summary, we have reported recently 
that Gd3+ complexes of amide conjugates of the DO3A-N-(-amino)propionate chelator are new leads 
for targeted, high relaxivity, safe CA for in vivo MRI.21 In this work we provide further evidence to 
support this claim, using simple design principles and robust chemistry accessible to all laboratories. 
 
Experimental 
Materials and Methods 
Chemicals were purchased from Sigma-Aldrich and used without further purification. Solvents used 
were of reagent grade and purified by usual methods. Cyclen was purchased from CheMatech, France. 
Reactions were monitored by TLC on Kieselgel 60 F254 (Merck) on aluminium support. Detection 
was by examination under UV light (254, 365 nm) and by adsorption of iodine vapour. Flash 
chromatography was performed on Kieselgel 60 (Merck, mesh 230-400). The relevant fractions from 
flash chromatography were pooled and concentrated under reduced pressure, T <313 K. Ion exchange 
chromatography was performed on Dowex1X2100-OH- resin (Sigma Aldrich). The resin was 
purchased as the Cl- form and converted to the OH- form by treatment with aqueous NaOH. 1H and 13C 
NMR spectra (assigned by 2D DQF-COSY and HMQC techniques) were run on a Varian Unity Plus 
300 NMR spectrometer, operating at 299.938 MHz and 75.428 MHz, for 1H and 13C, respectively. 
Chemical shifts () are given in ppm relative to the CDCl3 solvent (1H, 7.27; 13C, 77.36) as internal 
standard. For 1H and 13C spectra recorded in D2O, chemical shifts () are given in ppm relative to TSP 
as internal reference (1H, 0.0) and tert-butanol as external reference (13C, CH330.29). 
 
Synthesis of methyl 3-hydroxy-2-(4-(pyren-1-yl)butanamido)propanoate (3): 
To a solution of HCl,H-Ser-OMe (1) (5.0 mmol, 0.778 g) and triethylamine (10 mmol) in acetonitrile 
(5.0 mL), was added 1-pyrenebutyric acid (2) (5.0 mmol, 1.44 g), 1-hidroxybenzotriazole (HOBt) (5.0 
mmmol, 0.675 g) and dicyclohexylcarbodiimide (DCC) (5.5 mmol, 1.13 g).  The reaction mixture was 
left stirring at room temperature for 18 hours. The reaction mixture was filtered and the solvent was 
removed under reduced pressure. The residue was dissolved in ethyl acetate (100 mL), washed with 
KHSO4 1M, NaHCO3 1M and brine (3 x 30 mL each) and dried over MgSO4. The solvent was 
removed to give 3 (1.70 g, 87%) as a yellow oil. 1H NMR (300 MHz, CDCl3):  = 2.17-2.26 (m, 2H, 
CH2), 2.37 (t, J=7.2 Hz, 2H, CH2), 3.35-3.41 (m, 2H, CH2), 3.76 (s, 3 H,CH3), 3.86-4.00 (m, 2 H, -
CH2 Ser), 4.66-4.71 (m, 1 H, -CH Ser), 6.49 (d, J=7.2 Hz, 1H, NH), 7.84 (d, J=7.8 Hz, 1H, ArH), 
7.96-8.02 (m, 3H, ArH), 8.08-8.17 (m, 4H, ArH), 8.28 (d, J=9.3 Hz, 1H, ArH) ppm.13C NMR (75.4 
MHz, CDCl3):  = 27.14 (CH2), 32.58 (CH2), 35.69 (CH2), 52.72 (CH3), 54.61 (CH), 63.40 
(CH2),123.28 (CH), 124.74 (CH), 124.75 (CH), 124.88 (CH), 124.91 (C), 125.02 (C), 125.81 (CH), 
126.68 (CH), 127.33 (CH), 127.37 (CH), 127.42 (CH), 128.70 (C), 129.91 (C), 130.82 (C), 131.24 (C), 
135.61 (C), 170.93 (C=O), 173.20 (C=O) ppm. HRMS (ESI): m/z: calcd. for C24H23NNaO4, [M+Na]
+: 
412.1520; found 412.1519. 
 
Synthesis of methyl 2-[N-(tert-butoxycarbonyl)-4-(pyren-1-yl)butanamido]acrylate (4): 
To a solution of Pyr-Ser-OMe (3) (5.0 mmol, 1.95 g) in dry acetonitrile (5.0 mL) was added 4-
dimethylaminopyridine (DMAP) (1.7 mmmol, 0.213 g) and tert-butyldicarbonate (17.5 mmol, 3.82 g). 
The reaction mixture was left stirring at room temperature for 24 hours. The solvent was removed 
under reduced pressure and the residue was dissolved in ethyl acetate (100 mL). The organic layer was 
washed with KHSO4 1M, NaHCO3 1M and brine (3 x 30 mL, each), dried over MgSO4 and the solvent 
removed under reduced pressure to give 4 (1.91 g, 81%) as a yellow oil. 1H NMR (400 MHz, CDCl3): 
 = 1.46 (s, 9 H, CH3 Boc), 2.23-2.27 (m, 2H, CH2), 3.17 (t, J= 6.8 Hz, 2H, CH2), 3.42-3.46 (m, 2H, 
CH2), 3.81 (s, 3H, OCH3), 5.67 (s, 1H, CH2), 6.48 (s, 1H, CH2), 7.91 (d, J= 7.6 Hz, 1H, ArH), 7.98-
8.06 (m, 3H, ArH), 8.11-8.13 (m, 2H, ArH), 8.16-8.18 (m, 2H, ArH), 8.37 (d, J= 9.2 Hz, 1H, ArH) 
ppm. 13C NMR (100.6 MHz, CDCl3): = 26.82 (CH2), 27.81 [C(CH3)3], 32.91 (CH2), 37.44 (CH2), 
52.47 (OCH3), 83.72 [OC(CH3)3], 123.56 (CH), 124.67 (CH), 124.77 (CH), 124.79 (CH2), 124.99 (C), 
125.06 (C), 125.74 (CH), 125.90 (CH), 126.58 (CH), 127.29 (CH), 127.34 (CH), 127.47 (CH), 128.77 
(C), 129.88 (C), 130.93 (C), 131.40 (C), 135.55 (C), 136.29 (C), 151.52 (C=O), 163.68 (C=O), 175.21 
(C=O) ppm. HRMS (ESI): m/z: calcd. for C29H29NNaO5, [M+Na]
+: 494.1943; found 494.1929. 
 
Synthesis of (2-(N-t-butoxycarbonyl)pyrenebutyramido)-methoxycarbonylethyl-1,4,7,10-
tetrazacyclododecane (monoalkylated cyclen) (6): K2CO3 (1.47 g, 10.6 mmol) was added to a 
solution of cyclen (5) (0.460 g, 2.67 mmol) in MeCN (30 mL). To this solution was added 
(pyrene)Boc-Δ-AlaOMe (4) (0.840 g, 1.78 mmol). The suspension was vigorously stirred at room 
temperature for 5 hours. The suspended solid was removed by filtration and the solvent was 
evaporated under reduced pressure. The residue was purified by flash chromatography (100% 
CH2Cl2 CH2Cl2/EtOH/NH4OH/H2O (50:50:1:1)) to afford compound 6 as a viscous light yellow oil 
(0.95 g, 83%).1H NMR (300 MHz, CDCl3): δ = 1.47 (s, 9H, Boc), 2.20 (m, 2H, CH2CH2CH2), 2.50-
2.80 (m, 16H, N(CH2)2N-cyclen), 3.01-3.18 (m, 2H, C(O)CH2CH2), 3.38-3.50 (m, 2H, CH2CH2-
Pyrene), 2.77 (dd, J= 14.4 and 6.9 Hz, 1 H, NCHaHbCH), 3.38 (dd, J= 14.25 and 5.1 Hz, 1 H, 
NCHaHbCH), 3.70 (s, 3H, OMe), 5.51 (t, J= 6.9 and 4.8 Hz, 1H, NCHaHbCH), 7.85-8.40 (9H, m, Ar). 
13C NMR (75.4 MHz, CDCl3): δ= 26.98 (CH2-Ser), 27.88 (C(CH3)3), 32,85 (CH2), 37,79 (CH2), 
45.02 (CH2), 45.37 (CH2), 46.75 (CH2), 51.22 (CH2), 52.22 (OCH3), 53.52 (CH), 55.97 (NCH2CH), 
84.31 (C(CH3)3), 123,41 (CH-Ar), 124,70 (CH-Ar), 124.72 (CH-Ar), 124,87 (CH-Ar), 125,83 (CH-
Ar), 126,67 (CH-Ar), 127.37 (2x(CH-Ar)), 127,45 (CH-Ar), 128,01 (C-Ar), 128,62 (C-Ar), 129.86 (C-
Ar), 130,82 (C-Ar), 131.31 (C-Ar), 136.13 (C-Ar), 151.86 (NC(O)), 170.63 (C(O)OCH3), 175,37 
(C(O)CH2). HRMS (ESI): m/z: calcd for C37H50N5O5, [M+H]
+: 644.3812, found: 644.3807. 
 
Synthesis of 2-pyrenebutyramido-methoxycarbonylethyl-4,7,10-tris-(ethoxycarbonylmethyl)-
1,4,7,10 tetrazacyclododecane (tetraalkylated cyclen) (7):  
A solution of monoalkylated cyclen (6) (0.860 g, 1.33 mmol) in trifluoroacetic acid in dichlorometane 
(60%, 25 mL) was stirred overnight at room temperature. The solvent was evaporated at reduced 
pressure and the residue was re-dissolved in dichlorometane. This procedure was repeated several 
times to give a light yellow thick oil. 1H NMR spectroscopy (CDCl3) revealed the disappearance of the 
signal assigned to the tert-butyloxycarbonyl group in compound 6. K2CO3 (2.20 g, 15.96 mmol) was 
added to a solution of deprotected 6 (1.33 mmol, quantitative deprotection was assumed) in MeCN (30 
mL). To this suspension was added ethyl bromoacetate (0.55 mL, 4.66 mmol). The suspension was 
vigorously stirred at room temperature for 2.5 hours. The solid in suspension was removed by 
filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash 
chromatography (100% CH2Cl2 CH2Cl2/EtOH (1:1)) to afford compound 7 (0.632 g, 59%) as a 
white foam. 1H NMR (300 MHz, CDCl3): δ = 1.26 (m, 9H, 3xCH2CH3), 2.20 (m, 2H, CH2CH2CH2), 
2.56 (m, 2H, C(O)CH2CH2), 2.60-2.90 (m, 6H, NCH2C(O)), 2.90-3.70 (m, 16H, N(CH2)2N), 3.37 (m, 
2H, CH2CH2Pyrene), 3.73 (s, 3H, OMe), 3.92 (bd, 2H, NCH2CH), 4.09 (m, 6 H, CH2CH3), 4.94 (bd, 
1H, NCH2CH), 7.80-8,40 (9H, m, Ar). 
13C NMR (75.4 MHz, CDCl3): selected signals: 13.84, 13.88, 
14.05 (CH2CH3), 27.36 (CH2-Ser), 32,79 (CH2), 35,45 (CH2), 48.21 (CH), 48.91 (CH2), 50.34 
(CH2), 51.36 (CH2), 52.47 (OCH3), 53.01 (CH2), 53.60 (CH2CH), 54.90 (CH2), 55.19 (CH2), 55.71 
(CH2), 55.98 (CH2), 58.25 (CH2), 60.51 (CH2), 60.99, 61.20, 61.55 (OCH2), 123,63 (CH-Ar), 124,62 
(CH-Ar), 124.75 (CH-Ar), 124,85 (CH-Ar), 125,76 (CH-Ar), 126,51 (CH-Ar), 127.18 (CH-Ar), 
127,41 (CH-Ar), 127,46 (CH-Ar),  128,67 (C-Ar), 129,72 (C-Ar), 130.87 (C-Ar), 131.32 (2x(C-Ar)), 
136.43 (C-Ar), 136.53 (C-Ar), 170.312 (C(O)OCH3), 170.53 (C(O)OCH2), 173.15 (C(O)OCH2), 
173.55 (C(O)OCH2), 174.31 (NC(O)). HRMS (ESI): m/z: calcd for C44H60N5O9, [M+H]
+: 802.4391, 
found: 802.4386. 
 
Synthesis of 2-pyrenebutyramido-carboxyethyl-4,7,10-tris-(carboxymethyl)-1,4,7,10-
tetrazacyclododecane (L) (DO3A-N-(-pyrenebutyramido)propionate metal chelator): 
Compound (7) (0.566 g, 0.710 mmol) was dissolved in a mixture made up of 20 mL of water and 20 
mL of ethanol. The solution was adjusted to pH 10-11 by adding small portions of Dowex 1X2-100-
OH- resin. The suspension was kept stirring at room temperature for 2 hours. The wet resin was 
transferred into a chromatography column, washed with water (~ 50 mL) and eluted with 0.1 M 
hydrochloric acid, followed by a mixture of hydrochloric acid 0.1M/Etanol (1:1). The relevant 
fractions, identified by TLC (ethanol/water 1/1, revelation with iodine vapour and analysis under UV 
light 365 nm) were pooled, concentrated at room temperature and further dried under vacuum to afford 
the final compound, as hydrochloride, as a light yellow solid (0.31 g, 62%).1H NMR (300 MHz, 
D2O/MeOD): δ= 2.13 (bb, 2H, CH2CH2CH2), 2.50 (m, 2H, C(O)CH2CH2), (2.9-3.6, broad, overlapped 
signals with a integration corresponding to, 18H, 4xN(CH2)2N and NCH2CH), 3.33 (m, 2H, 
CH2CH2Pyrene), 3.81 (broad, overlapped signals with a integration corresponding to 6H, NCH2), 4.76 
(m (br), 1H, CH), 7.80-8.40 (9H, m, Ar). 13C NMR (75.4 MHz, D2O/MeOD): selected signals: 28.22 
(CH2), 33,25 (CH2), 36,29 (CH2), 50.49 (bb, CH2), 54.95 (bb, CH2), 124,31 (CH-Ar), 125,44 (C-
Ar), 125,54 (C-Ar), 125,75 (CH-Ar), 125.85 (2x(CH-Ar)), 127,08 (CH-Ar), 127,50 (CH-Ar), 127.08 
(C-Ar), 128,18 (CH-Ar), 128.37 (CH-Ar), 128,46 (CH-Ar), 129.41 (C-Ar), 130.75 (C-Ar), 131.75 (C-
Ar), 137.27 (C-Ar),177.47 (NC(O)). HRMS (ESI): m/z: calcd for C37H46N5O9, [M +H]
+: 704.3296, 
found: 704.3290. 
 
1H and 17O NMR and 1H NMRD experiments  
Sample preparation 
To an aqueous solution of the ligand (pH 5) was added drop-wise an aqueous solution of the 
corresponding LnCl3.xH2O salt in a 1:1 mole ratio. The solution was stirred at room temperature over 
1 hour while keeping its pH at around 5.7 by adding aqueous NaOH. The solution was left stirring at 
room temperature overnight.  Concentration under reduced pressure afforded off-white solids. 
Solutions for NMR measurements (20 mM) were obtained by dissolution of appropriate amounts of 
solid complexes in D2O (V= 0.75 mL). Proton 1D spectra of paramagnetic (Sm
3+ and Eu3+) and 
diamagnetic (La3+) complexes were obtained at 298 K on a Varian VNMRS 600 (14.09 T, 600.14 
MHz) NMR spectrometer. 
The GdL complex solutions for 17O NMR and 1H NMRD experiments were prepared by mixing 
equimolar amounts of GdCl3 and ligand. A slight excess (5%) of ligand was used. The solution was 
stirred at room temperature over 1 hour while keeping its pH at around 5.7 by adding aqueous NaOH. 
The solution was left stirring at room temperature overnight. The absence of free metal was checked 
by the xylenol orange test.56,57 The pH of the stock solution was adjusted to the desired value by 
adding aqueous NaOH (0.1 mM). 17O-enriched water (17O: 11.4%) was added to the solutions for 17O 
measurements to improve sensitivity. The final concentration of the complex solution was 17.56 mmol 
kg-1 at pH = 6.90. For the NMRD experiments 5.0 mM and 0.1 mM solutions of the complex at pH 
6.98 were used. 
 
17O NMR experiments 
Variable-temperature 17O NMR measurements were performed on a Bruker Avance-500 (11.7 T) 
spectrometer. A BVT-3000 temperature control unit was used to stabilize the temperature, measured 
by a substitution technique. The samples were sealed in glass spheres that fitted into 10 mm o.d. NMR 
tubes to eliminate susceptibility corrections to the chemical shifts.53 Longitudinal relaxation rates 
(1/T1) were obtained by the inversion recovery method, and transverse relaxation rates (1/T2) by the 
Carr-Purcell-Meiboom-Gill spin-echo technique. Acidified water, pH 3.4, was used as external 
reference.  
 
 
NMRD measurements 
The measurements were performed using a Stelar Spinmaster FFC NMR relaxometer (0.01–20 MHz) 
equipped with a VTC90 temperature control unit. At higher fields, the 1H relaxivity measurements 
were performed on a Bruker Electromagnet at the frequencies of 30 MHz, 40 MHz, 60 MHz and 80 
MHz. In each case, the temperature was measured by a substitution technique. Variable temperature 
measurements were performed at 25 and 37◦C. 
 
Relaxivity studies of pH dependence and Zn2+ transmetallation 
The transmetallation reaction of GdL with Zn2+ was studied by following the time dependent decrease 
of the water proton longitudinal relaxation rate, R1, of a phosphate-buffered saline solution (PBS, pH 
7.1, 10 mM) containing 1.5 mM of GdL after adding an equimolar amount of ZnCl2 while the sample 
was vigorously stirred.59 The water longitudinal relaxation rate was also measured as a function of 
time on the PBS buffered solution (pH 7.1, 10 mM) containing 2.5 mM GdL60 The pH dependence of 
the relaxivity of the GdLsolution was studied by adjusting (pH meter) the pH of a 1 mM solution of 
GdL in water with either NaOH or HCl solutions using a pH meter. A Bruker Minispec mq20 (20 
MHz, 298 K) relaxometer was used for all measurements. 
 
Fluorescence Measurements  
The absorption and the ligand-based fluorescence emission spectra of the free ligand L and the GdL 
complex were recorded, respectively, with a Jasco V-630 UV-Vis spectrophotometer and a HORIBA 
JobinYvon Fluoromax-4 spectrofluorimeter, equipped with a monochromator in both excitation and 
emission and a temperature controlled cuvette holder. Fluorescence spectra were corrected for the 
instrumental response of the system.  
The fluorescence quantum yields (s) were determined using the standard method.61,62 Anthracene in 
ethanol (Φr = 0.27)63 was used as reference. 
For the lanthanide centred fluorescence studies in the visible (Eu3+ and Tb3+) and in the NIR region 
(Nd3+, Yb3+), absorbance UV spectra were performed on an Uvikon spectrophotometer, while emission 
and excitation (lanthanide luminescence) spectra were measured using a modified Jobin-Yvon Horiba 
Fluorolog-322 spectrofluorimeter equipped with a Hamamatsu R928 detector (for the visible domain) 
and a DSS-IGA020L (Electro-Optical Systems, Inc.) detector (for the NIR domain). Luminescence 
and excitation spectra were corrected for variations in lamp output, non-linear response of the detector 
and the use of neutral density filters (where applicable). For collecting luminescence data, samples 
were placed into quartz Suprasil cells (Hellma® 115F-QS, bandpass 0.2 cm). 
Biodistribution studies 
153SmL for in vivo experiments was prepared by adding 1 mCi of [153Sm]Cl3 (produced at the Instituto 
Tecnológico e Nuclear, Lisbon, Portugal with a specific radioactivity > 5 GBq/mg) to a solution of 1 
mg of the chelator in acetate buffer (400 μL, 0.4 M, pH 5) and heated at 80 ºC for ca 1 hour. The 
radiochemical purity of 153SmL1 was determined by TLC. The percentage of chelated metal was found 
to be greater than 95%. 
Groups of four animals (Wistar rat males weighting ca 200 g) were anaesthetized with Ketamine (50.0 
mg/mL)/chloropromazine (2.5%) (10:3) and injected in the tail vein with ca 100 Ci of the tracer. 
Animals were sacrificed 1 and 24 hours later and the major organs were removed, weighted and 
counted in a  well-counter. 
 
Size distribution 
The size distribution of particles in a (micellar) solution of GdL at a concentration well above the cmc 
(5.0 mM, pH 7.0) was determined with a Malvern Zetasizer, NANO ZS (Malvern Instruments Limited, 
UK), using a He-Ne laser (= 633 nm) and a detector angle of 173º. The GdL solution in a polystyrene 
cell (1 mL) was analysed at 25 ºC. The mean hydrodynamic radius (z-average) and a width parameter 
for the distribution, polydispersity or polydispersity Index (PdI) were calculated from the intensity of 
the scattered light. In the present work, the intensity-based z-average parameter was considered the 
best approach to the actual particle size.  
 
Data Analysis. Data obtained in 17O NMR, 1H NMRD, Luminescence and Quantum Yield 
measurement studies were processed in OriginLab Pro 8 SRO. Data from relaxometric and 
transmetallation studies were processed with Microsoft Office Excel 2007. 
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 z-average 
(r. nm) 
Radius (nm) 
(% volume) 
Radius (nm) 
(% intensity) 
GdL 
(5 mM, pH 7.0, 25 ºC) 
48.9 1.57 (100%) 73.1 (61.9%) 
1.74 (38.1%) 
 
Figure S1. Size distribution in: a) volume (%); b) intensity (%) for a GdL solution (5.0 mM, pH 7.0, 25 ºC) at a 
concentration well above the cmc (0.6 mM). 
 
 
 
 Figure S2. Temperature dependence of the water proton relaxivity for GdL (20MHz , 1mM, pH 6.0).  
  
 
 
Figure S3. pH dependence of the water proton relaxivity for GdL (20 MHz, 1 mM, 25 ºC).  
 
 
 
 
Figure S4. Evolution of the relative water proton paramagnetic longitudinal relaxation rate R1p(t)/R1p(0) (20 MHz, pH 7.1, 
25 ºC) for a 1.5 mM solution of GdL in 10 mM phosphate buffer(○) and in phosphate buffer containing an equimolar 
amount of Zn2+ (●). 
 
  
 
Figure S5. UV-Vis spectra for the free ligand L and for the GdL complex in water (1.0x10-5 M, pH 7.0, 25 ºC). 
 
 
 
Figure S6. Fluorescence spectra for free ligand L in non-deoxygenated water (pH 7.0, 25 ºC) over the concentration range 
5x10-5 - 5x10-3 mol.dm-3 (exc= 345 nm). 
 
 
 
 
 
 Figure S7. Changes in the emission properties of the free ligand L as the ratio of the fluorescence emission intensity for the 
excimer (490 nm) and for the monomer (377 nm) (IE/IM) as function of ligand concentration. Line fitted to equation S1.  
 
The experimental data in Figure 5 (manuscript) and Figure S6 were fitted (Prima GraphPad) to a sigmoidal 
model (equation S1).[1,2] 
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Equation S1 
c - complex (GdL)) or free ligand (L)  concentration; 
A1 and A2 - represent the limits of sigmoidal function that describes the behaviourof d(IExc/IMono)/dc (derivative of IExc/IMono 
in order to c);: 
d - is the time constant of the function and is related to the range of concentration over which the abrupt change in IExc/IMono 
occurs; 
cmc - is the center of the sigmoidal function. 
 
Table S1. Best fit values for the fitting (Prima GraphPad) of the experimental data of IExc/IMono vs [GdL] (Figure 5 in 
manuscript and Figure S6) to equation S1.  
 
Best-fit values GdL 
(IExc/IMono)0 -1.764 
A1 0.3660 
d 0.007795 
A2 3.119 
cmc 0.6454 
Std. Error  
(IExc/IMono)0 0.007529 
A1 0.06346 
d 71873 
A2 0.002088 
cmc 0.01454 
 
 
 
The E titration data (Figure 7 in manuscript) were fitted to equation S2 with n, number of equivalent binding sites, fixed to 
1.   
 
Equation S2 
n - number of equivalent binding sites, fixed to 1 in the fitting. 
r1f  - relaxivity of the free GdL form, non-complexed with HSA 
r1c - relaxivity of the GdL form bound to HSA 
c1 - analytical concentration of GdL 
cHSA - analytical concentration of HSA 
KA -  association constant GdL/HSA 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2. Biodistribution, stated as percentage of injected dose per gram of organ 
(%ID/g ±SD), of 153SmL in Wistar rats at  1 and 24 hours after i.v. injection. 
Results are the mean of 4 animals. 
 
Organ 
1 hour 
%ID+SD 
24 hours 
%ID+SD 
Blood 
Liver 
Spleen 
Kidney 
Heart 
Lung 
S. Intest. 
L. Intest. 
Bone 
Muscle 
Brain + Cerebellum 
0.3071±0.0290 
0.2095±0.0617 
0.1784±0.0581 
0.0629±0.0105 
0.0385±0.0224 
0.1084±0.0220 
0.0352±0.0190 
0.0125±0.0015 
0.0365±0.0078 
0.0095±0.0048 
0.0213±0.0134 
0.0015±6.5x10-5 
0.4701±0.1216 
0.3012±0.1646 
0.0242±0.0026 
0.0044±0.0014 
0.0274±0.0104 
0.0066±0.0011 
0.0035±0.0029 
0.0411±0.0057 
0.011±0.00010 
0.0007±8.15x10-5 
APPENDIX 1: Analysis of NMRD and 17O NMR data 
NMRD and 17O NMR data have been analysed within the framework of Solomon-Bloembergen-
Morgan theory.  
17O NMR spectroscopy 
From the measured 17O NMR relaxation rates and angular frequencies of the paramagnetic solutions, 
1/T1 , 1/T2 and , and of the acidified water reference, 1/T1A, 1/T2Aand , one can calculate the 
reduced relaxation rates and chemical shifts, 1/T2rand r, which may be written as in Equations (A1)-
(A3), where, 1/T1m, 1/T2m is the relaxation rate of the bound water and m is the chemical shift 
difference between bound and bulk water, m is the mean residence timeor the inverse of the water 
exchange rate kexandPm is the mole fraction of the bound water. [3, 4]
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The outer sphere contributions to the 17O relaxation rates 1/T1OS and 1/T2OS can are neglected according 
to previous studies.[5] Therefore, Equations (A1-A2) can be further simplified into Equations (A4) and 
(A5):  
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The exchange rate is supposed to obey the Eyring equation. In equation (A6) S‡andH‡ are the 
entropy and enthalpy of activation for the water exchange process, and kex
298 is the exchange rate at 
298.15 K. 
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In the transverse relaxation, the scalar contribution, 1/T2sc, is the most important [Equation (A7)]. 1/s1 
is the sum of the exchange rate constant and the electron spin relaxation rate [Equation (A8)].  
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The 17O longitudinal relaxation rates in Gd3+ solutions are the sum of the contributions of the dipole-
dipole (dd) and quadrupolar (q) mechanisms as expressed by Equations (A11-A13) for non-extreme 
narrowing conditions, where γSis the electron and γIis the nuclear gyromagnetic ratio (γS= 1.761011 
rad s-1 T-1, γI=-3.626107 rad s-1 T-1), rGdO is the effective distance between the electron charge and the 
17O nucleus, I is the nuclear spin (5/2 for 17O),  is the quadrupolar coupling constant and is an 
asymmetry parameter : 
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(A11) 
In Equation (A3) the chemical shift of the bound water molecule, m, depends on the hyperfine 
interaction between the Gd3+ electron spin and the 17O nucleus and is directly proportional to the scalar 
coupling constant, 

A
, as expressed in Equation (A12).[6] 
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          (A12) 
The isotopic Landé g factor is equal to 2.0 for the Gd3+, B represents the magnetic field, and kB is the 
Boltzmann constant. 
The outer-sphere contribution to the chemical shift is assumed to be linearly related to Δωm  by a 
constant Cos [Equation (A13)]. [7] 
mosos Δω=CΔω  
         (A13) 
 
NMRD 
The measured longitudinal proton relaxation rate, R1
obs
= 1/T1
obs, is the sum of a paramagnetic and a 
diamagnetic contribution as expressed in Equation (A14), where r1 is the proton relaxivity: 
][+R=R+R=R +dpdobs 311111 Gdr           (A14) 
The relaxivity can be divided into an inner and an outer sphere term as follows: 
1os1is1 r+r=r           (A15) 
The inner sphere term is given in Equation (A16), where q is the number of inner sphere water 
molecules. [8] 
mH
1m
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The longitudinal relaxation rate of inner sphere protons, 1/T1m
H is expressed by Equation (A11), where 
rGdH is the effective distance between the electron charge and the 
1H nucleus, I is the proton 
resonance frequency and S is the Larmor frequency of the Gd3+ electron spin. 
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whereRH is the rotational correlation time of the Gd-Hwater vector.  
For small molecular weight chelates (fast rotation), the spectral density function is expressed as in 
Equation (A19). 
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For slowly rotating species, the spectral density functions are described the Lipari-Szabo approach.[9] 
In this model we distinguish two statistically independent motions; a rapid local motion with a 
correlation time land a slower global motion with a correlation time g. Supposing the global 
molecular reorientation is isotropic, the relevant spectral density functions are expressed as in 
Equations (A20-A24), where the general order parameter S2 describes the degree of spatial restriction 
of the local motion. If the local motion is isotropic, S2 = 0; if the rotational dynamics is only governed 
by the global motion, S2 = 1. 
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The rotational correlation time, RH is assumed to have simple exponential temperature dependence 
with an ER activation energy as given in Equation (A25). 
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The outer-sphere contribution can be described by Equations (A26 and A27) where NA is the Avogadro 
constant, and Jos is its associated spectral density function as given by Equation (A15). [10, 11]
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 The longitudinal and transverse electronic relaxation rates, 1/T1e and 1/T2e are expressed by Equation 
(A28 and A29), where v is the electronic correlation time for the modulation of the zero-field-splitting 
interaction, Ev the corresponding activation energy and 2 is the mean square zero-field-splitting 
energy. We assumed a simple exponential dependence of vversus 1/T as written in Equation (A30). 
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The diffusion coefficient for the diffusion of a water proton away from a Gd3+ complex, DGdH, is 
assumed to obey an exponential law versus the inverse of the temperature, with activation energy 
EDGdH, as given in Equation (A31). DGdH
298
is the diffusion coefficient at 298.15K. 
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